The elimination of tumor cells by apoptosis is the main mechanism of action of chemotherapeutic drugs. More recently, autophagic cell death has been shown to trigger a nonapoptotic cell death program in cancer cells displaying functional defects of caspases. Fenretinide (FenR), a synthetic derivative of retinoic acid, promotes growth inhibition and induces apoptosis in a wide range of tumor cell types. The present study was designed to evaluate the ability of fenretinide to induce caspase-independent cell death and to this aim we used the human mammary carcinoma cell line MCF-7, lacking functional caspase-3 activity. We demonstrated that in these cells fenretinide is able to trigger an autophagic cell death pathway. In particular we found that fenretinide treatment resulted in the increase in Beclin 1 expression, the conversion of the soluble form of LC3 to the autophagic vesicle-associated form LC3-II and its shift from diffuse to punctate staining and finally the increase in lysosomes/autophagosomes. By contrast, caspase-3 reconstituted MCF-7 cell line showed apoptotic cell death features in response to fenretinide treatment. These data strongly suggest that fenretinide does not invariably elicit an apoptotic response but it is able to induce autophagy when apoptotic pathway is deregulated. The understanding of the molecular mechanisms involved in fenretinide action is important for the future design of therapies employing this retinoid in breast cancer treatment.
Introduction
A number of studies have shown that vitamin A and its biological active derivative retinoids regulate many important cellular processes, including growth, differentiation and apoptosis. 1, 2 From a clinical point of view, retinoic acid and some synthetic retinoids have provided opportunities for cancer treatment and prevention, although natural retinoids show only a moderate activity against most cancer cell types and also induce differentation rather than apoptosis rendering tumor cells resistent to chemotherapy; 3 these negative aspects represent a strong limit to their clinical applications. On the contrary, some synthetic derivatives of retinoic acid, such as fenretinide (4-HPR), promote growth inhibition and are able to induce apoptosis rather than differentation, 4 showing synergistic responses with chemotherapeutic drugs in a wide range of tumor cell types. [5] [6] [7] In small cell lung carcinoma cells fenretinide acts synergistically with cisplatin or etoposide to arrest cell growth 5 and the pretreatment of breast cancer cells with fenretinide also increases growth inhibition in response to cisplatin. 6 The signaling pathway of fenretinide-induced apoptosis is partially mediated by RAR (retinoic acid receptor) activation and transactivation of target genes but also by the production of reactive oxygen species (ROS) 8 and ceramide accumulation. The antiproliferative effects of fenretinide in breast cancer cells have been correlated to free radical production which is one of the mechanisms suggested for the cell death effects of this compound. 9 Fenretinide-induced apoptosis of neuroectodermal tumor cells is mediated by caspases activated by the release of cytochome c due to mitochondrial membrane permeabilization mediated by the Bcl-2 family members Bax and Bak. [10] [11] [12] In vivo, fenretinide selectively accumulates in breast tissue and inhibits rat mammary carcinogenesis; 13 moreover it has been recently demonstrated that this compound induces a significant risk reduction of second breast cancer. 14 Therefore, fenretinide or similar compounds may provide opportunities for novel approaches to cancer therapy.
Autophagic cell death is another important physiological form of programmed cell death, characterized by massive degradation of cellular contents, intracellular membrane/vesicle reorganization and lysosomal activity. 15 Although the elimination of tumor cells by apoptosis is the main mechanism of action of chemotherapeutic drugs, more recently it has been shown that autophagy is involved in stress responses and tumorigenesis. In fact, in the last few years autophagy has been proposed as one of the survival mechanisms for cancer cells in response to radiation and chemotherapeutic agents; 16, 17 however, it may also play a role in the elimination of cancer cells via a caspase-independent death. 18 In the present study, we demonstrated that in the MCF-7 (caspase-3-defective) human mammary carcinoma cell line, fenretinide treatment results in autophagic cell death induction; these data suggest that this synthetic retinoid is able to activate an alternative cell death pathway in cancer cells with apoptotic defects offering a promising approach to enhance efficiency of cancer chemotherapy.
Results
The present study was designed to evaluate the ability of fenretinide to induce caspase-independent cell death in tumor cells. To this aim we decided to use the human mammary carcinoma cell line lacking caspase-3 (MCF-7/7.0.3) and the same cell line reconstituted with caspase-3 (MCF-7/7.3.28). 19 It has been shown that in MCF-7 human breast cancer cell the resistance to apoptotic stimuli is the result of a 47 bp deletion in exon 3 of CASP-3 gene. 19, 22, 23 Different experimental studies have shown that in MCF-7 cell line, caspase-3 is essential for apoptosis induction in response to different chemotherapeutic drugs or ionizing radiation; in fact, in these cells, the overexpression of caspase-3 is able to restore sensitivity to these stimuli. [23] [24] [25] [26] [27] We first analysed in caspase-3-defective (MCF-7/7.0.3) and caspase-3-expressing (MCF-7/7.3.28) cells the effect of fenretinide treatment by using methods detecting classic parameters of apoptosis, such as chromatin condensation or internucleosomal DNA fragmentation. Although after 24 h treatment with 5 μM fenretinide the cells became rounded and detached from culture plates (data not shown), in MCF-7/7.0.3 cell line we did not observe a significant increase in apoptosis as measured by TUNEL staining and cytofluorimetric analysis (Fig. 1A and B) . However we observed a strong upregulation of GADD153 response gene which is normally overexpressed in response to fenretinide (Fig. 1C) . 28 The biological activity of the synthetic retinoid was also monitored by western blot analysis of caspase-3 activation in the MCF-7 cells stably transfected with caspase-3 expression construct (MCF-7/7.3.28) (Fig. 1D) . Taken together these results suggest that caspase-3-defective MCF-7 cells are sensitive to fenretinide, but changes acquired upon FenR-treatment did not resemble those of apoptotic cells.
Studies from other group have demonstrated that breast cancer cells are generally resistent to conventional chemoterapeutics drugs (such as cisplatin), 29 but they are sensitive to tamoxifen administration, which however results in the induction of the alternative autophagic cell death. 30 Considering these observations we wondered if, in this cell line, FenR treatment was able to trigger the same cell death pathway. To this aim, we performed a time course viability assay after 24 and 48 hours FenR administration, observing a cell death response which was particularly evident after 48 hours treatment (Fig. 1E) . Moreover, in order to verify whether this cytotoxic effect was due to autophagy induction, fenretinide was administered in the presence or in the absence of the autophagic inhibitor 3-Methyladenine (3-MA) (Fig. 1E) . Interestingly, our data indicated that 3-MA pretreatment resulted in the complete inhibition of fenretinide induced cell death, suggesting the involment of autophagy in the cellular response to this synthetic retinoid. In order to support this notion, we used other different experimental approches to study autophagy. We analysed both in MCF-7/7.0.3 and MCF-7/7.3.28 the expression level of Beclin 1, which is necessary for autophagy function. The results obtained indicated that after 24 h fenretinide treatment the endogenous protein level of Beclin 1 was significantly increased only in caspase-3-defective cells (Fig. 1F) . The observed Beclin-1 upregulation in these cells is comparable to that induced by tamoxifen treatments (Fig. 1G) .
During autophagosome formation, LC3-I is converted to LC3-II and this represent a key event in the regulation of this phenomenon, thus we examinated the effect of fenretinide on LC3 conversion in MCF-7/7.0.3 treated cells (Fig. 1H ). The data obtained by Western blot analysis, indicated the selective accumulation of LC3-II in these cells following FenR treatment. Moreover we found an increase in lysosomes/autophagosomes (Lysotracker red fluorescent dye) after 5 μM fenretinide treatment in MCF7 caspase-3-defective cells (Fig.  1I ). To further confirm that FenR administration was able to induce autophagic cell death in MCF-7/7.0.3 cell line, we also performed ultrastructural analysis (Fig. 1J ). After 24 h FenR treatment, we observed in the cytoplasm of these cells the appearance of multyple empty vacuoles and some autophagic vacuoles which are typical features of autophagy (Fig. 1J , part c-f ).
These results strongly suggest that fenretinide does not invariably elicit an apoptotic response but it is able to induce autophagy when the apoptotic pathway is deregulated.
We finally decided to study fenretinide-induced autophagy by monitoring the redistribution of the autophagosome marker LC3 from a diffused localization to a punctuated pattern. To this aim caspase-3-defective MCF-7 cells (MCF-7/7.0.3) and those transfected with the caspase-3 expression construct (MCF-7/7.3.28) were infected with a retroviral construct carring GFP-LC3. 21 In MCF-7/GFP-LC3 caspase-3 defective cells, LC3 produced a diffuse staining in the absence of treatment ( Fig. 2A ) as well as after other anticancer drugs (cisplatin and etoposide) (Fig. 2B ), whose treatments did not result in any cell death response (data not shown), according to the results by other groups. 30 By contrast, upon fenretinide treatment LC3 accumulates in autophagosomes only in MCF-7/GFP-LC3 caspase-3-defective cells, indicating the specificity of autophagy induction ( Fig.  2A) . In fact in the MCF-7/7.3.28 preapoptotic cells, following FenR treatment, GFP-LC3 produced a diffuse staining ( Fig. 2A) .
However, after nutrient deprivation which is a generic autophagic inducer, the shift from diffuse to punctate staining of the autophagosome marker LC3 was observed the MCF-7/7.0.3 (caspase-3 defective) as well as in MCF-7/7.3.28 (caspase-3 expressing) cells ( Fig. 2A) .
Fenretinide induced autophagic cell death in MCF-7/7.0.3 cells was further confirmed by the use of 3-MA which resulted in the diffuse staining of GFP-LC3 after FenR treatment as well as nutrient starvation ( Fig. 2C and D) and in the inhibition of LC3 cleavage (Fig. 2E) .
The results obtained strongly suggested that the cellular response to FenR is determined by the presence or the absence of caspase 3 expression. In order to support this notion, we decided to examinate the effect of fenretinide in MCF-7/7.3.28 cells treated with the pan-caspase inhibitor z-VAD. Worth noting, we observed the shift of GFP-LC3 lipidation from a diffuse to punctate staining pattern (Fig. 2F) . These data were further confirmed by the use of the isogenic ZR-75-1 cancer cell line, with functional caspase 3. As expected, in this cells FenR treatment resulted in the apoptotic response (data not shown), while the preatretment with z-VAD is able to shift the cellular response to an autophagic phenotype, as shown by Western blot analysis of LC3 cleavage (Fig. 2G ).
Discussion
Fenretinide holds great promise as a breast cancer chemopreventive and therapeutic agent 31, 32 because it selectively accumulates in breast tissues, 33 kills breast tumor cells 34 and renders mammary tissue less sensitive to carcinogens. 35 Recently a phase III clinical trial indicated that fenretinide effectively reduced local recurrent and contralateral breast cancer in premenopausal women. 36, 37 Thus, it appeared particularly attractive to evaluate the potentials of this agent for the chemoprevention of breast cancer.
Successful treatment of cancer cells with chemotherapeutic drugs is directly correlated with their ability to activate cell death pathways. Nevertheless, there are more types of cell death and in particular autophagy is the most relevant non-caspase programmed cell death pathway. In this work we analysed the effect elecited by fenretinide in the caspase-3-defective human breast cancer cell line (MCF-7/7.0.3) demonstrating that these cells are still sensitive to the synthetic retinoid analogue. Although this response resulted in cell death, the cells do not exhibit the typical apoptotic features which are detected, by contrast, in the caspase-3 reconstituted MCF-7/7.28.3 cells.
Recent studies from other groups reported that since MCF-7 cells do not express detectable levels of caspase-3 38 following different apoptotic stimuli, they die by alternative cell death pathways. 19 Interestingly, it has been demonstrated that in this cell line, treatment with tamoxifen as well as cellular starvation resulted in the activation of the autophagic cell death pathway. 39 Here we show that caspase-3-defective MCF-7 cells respond to fenretinide treatment dying by autophagy as demonstrated by the fact that the cytotoxic effect of this synthetic retinoid in these cells is coupled to several autophagic features such as the increase of Beclin 1 expression, LC3-II conversion and LC3-GFP punctate staining redistribution. Moreover, we demonstrated the specificity of FenR effect since in the same cell line (MCF-7/7.28.3) as well as in an isogenic cancer cell line (ZR-75-1) with functional caspase-3, we did not observe the induction of autophagic cell death following fenretinide administration. Both cell lines respond to this chemotherapeutic agent with apoptotic trasduction pathway, according to the data obtained using other drugs. 29 It is tempting to speculate that the fenretinide-dependent induction of Beclin 1 could be due to the drug-induced ceramide accumulation. 40 In fact, the promoter of beclin 1 gene displays several regulatory elements, including an SP1-binding site and affinity for E2F, which are typically controlled by ceramide. 41 It has been demonstrated that most of radiation and chemotherapy-resistant cancers have apoptotic defects; in particular, the mitochondria/cytochrome c pathway is frequently deregulated in human cancer cells. 42 Therefore the efficacy of the drugs may be enhanced substantially by the use of agents that can induce both caspase-dependent apoptosis and caspase-independent authophagic cell death. 43, 44 In fact, although autophagy has long been known as a protecting cellular mechanism which is used by some tumors to survive, it is now well accepted that it can also suppress tumor development; in fact, some of the autophagic regulators, such as Beclin 1 and death-associated protein kinase, 45, 46 are putative tumor suppressors. Activation of autophagic cell death program appears particularly useful for the treatment of cancer cell lines suffering from defective apoptosis and often resistent to the standard inducers of apoptosis. 47 However, so far, there is no cancer therapeutic approach that specifically targets autophagic cell death machinery.
Although studies from other groups have demonstrated that in MCF-7 human breast cancer cells fenretinide administration results in a significative increase of cell death levels, 48 the molecular mechanism and the relationship with caspase activation are unclear. Neverthless, since MCF-7 cells express a mutant nonfunctional caspase-3, it is likely that the antiproliferative effects of fenretinide in this cell line is mediated by a caspase-3-independent mechanism. In this context, our data demonstrated for the first time that fenretinide is able to induce autophagy in the MCF-7 caspase-3-defective cell line, indicating that it can be an important tool for the therapy of cancer cells evading apoptosis. It is of particular interest that, unlike serum starvation that induce autophagic cellular response both in caspase-3-defective and caspase-3-expressing cells, the synthetic retinoid can modulate a molecular switch between apoptosis and autophagy. This effect is dependent from the presence of caspase-3, in fact the inhibition of caspase-3 by the pan-caspase inhibitor z-VAD in MCF-7 cells (MCF-7/7.28.3) as well as in other isogenic cell line (ZR-75-1) shifts the cellular response to FenR to an autophagic phenotype. It is interesting to note that the ability of fenretinide to kill apoptosis defective cells is not shared by other chemotherapeutic agents such as cisplatin or etoposide.
Thus, the capability of fenretinide in initiating autophagic cell death when apoptotic pathway is deregulated, together with its synergistic effects with chemoterapeutic drugs makes this compound a promising therapeutic agent in treating cancers with apoptotic defects and also a useful experimental tool to study autophagy.
Materials and Methods
Cells culture. The MCF7/7.0.3 and MCF7/7.3.28 cells (kindly gift from Dr. G. Porter) 19 Cell death assay and apoptosis evaluation. TUNEL assay was performed using the in Situ Cell Death Detection Kit TMR red (Roche, USA) according to manufacturer's specifications and cells were analysed by flow cytometry. Apoptosis was monitored by evaluating the pre-G 1 cell population, after flow cytometric analysis as previously described. 20 For cell death assay MCF-7/7.0.3 cells were detached from the substrate, resuspended in Trypan blue solution (0.25% in PBS) and counted in a hemocytomoter under a light microscope. The experiments was performed three times and for statistical analysis Student's t-test was used.
Autophagy analysis by fluorescence and electron microscopy. Cells grown on coverslips were fixed in 4% paraformaldehyde and the shift from diffuse to punctate staining of the autophagosome marker GFP-LC3 was examined under Zeiss LSM 510 microscopy. The percentage of GFP-LC3-positive cells with GFP-LC3 punctate dots were performed as described. 21 A minimum of 50-100 cells per sample were counted in triplicate for each experiment. In the experiments with the caspase inhibitor zVAD, the cells were controstained with the fluorescence dye Hoescht-H 33258 (Molecular Probes; final concentration 10 μM). For statistical analysis Student's t-test was used. Autophagic vacuoles were detected also by LysoTraker (Molecular Probes), according to manufacturer's specifications. Cells were incubated with 50 nM LysoTraker for 30 min a 37°C and observed by fluorescence microscopy.
For electron microscopy investigations, cells were fixed with 2.5% glutaraldehyde in 0.1 mol/L cacodilate buffer pH 7.4 for 45 min at 4°C rinsed in cacodilate buffer 0.1 mol/L pH 7.4, post-fixed in 1% OsO 4 in 0.1 mol/L cacodilate buffer pH 7.4, dehydrated, embedded in Epon. Ultrathin sections were briefly contrasted with uranyl acetate and photographed in a Zeiss CM 900 electron microscope.
Western blot analysis. For western blot analysis cells were lysed in RIPA buffer as described. 20 Different amounts of total protein were separated by electrophoresis through SDS-PAGE gels and blotted into nitrocellulose. Monoclonal mouse-anti-GADD 153 (Santa Cruz, CA, USA) and Caspase 3, rabbit polyclonal antibodies (Cell Signaling) were used at 1:1000 dilution. Beclin 1 goat polyclonal (BD Biosciences, USA) and LC3 rabbit polyclonal or mouse monoclonal antibodies (MBL, Japan) were used at 1:500 dilution and visualized with an affinity-purified anti mouse/rabbit/goat peroxidase conjugated IgG diluted 1:5000 (Jackson Laboratories, PA, USA). A monoclonal mouse anti β-tubulin (Sigma) diluted 1:1000 was used as loading control.
Retroviral vectors and infection. For retroviral expression, the GFP-LC3 plasmid was obtained as described elsewhere. 21 Briefly, the LC3/Atg8 coding sequence obtained by PCR amplification from HeLa cDNA library was inserted into the EcoRI and SalI sites of pEGFP/C2 (Clontech) vector and trasfected into the HEK293 cell line using the calcium phosphate method. 50 μg of the retroviral vector were co-trasfected with 5 μg of an expression plasmid for the vescicular stomatitis virus G protein into a cell line 293 gp/bsr 3 and supernatant containing the retroviral particle was recovered after 48 h. MCF-7/7.0.3 and MCF-7/.3.28 were infected by incubation with retroviral-containing supernatant for 6-8 h. 
